Navigation Links
Celsion Reports Third Quarter 2010 Financial Results and Provides Business Update
Date:11/15/2010

to Treat Primary Liver Cancer from the FDA;
  • NCI Consensus published in Journal of Clinical Oncology recommended the Phase III HEAT study as a Priority Clinical Trial for HCC;  
  • Positive FDA guidance relating to 505(b)(2) regulatory submission received for the Company's New Drug Application for ThermoDox® to Treat Primary Liver Cancer;
  • ThermoDox® clinical data presented at the 2010 Breast Cancer Symposium;
  • SBIR grant received to expand technology platform; and
  • Celsion presented at two Healthcare Conferences in New York City.

  • The Company is holding a conference call to provide a business update and discuss the third quarter 2010 results at 3:00 p.m. Eastern Time on November 15, 2010. To participate in the call, interested parties may dial 1-888-218-8172 (Toll free U.S./Canada) or 1-913-312-9313 (Toll/International) and use Conference ID: 4428936 to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the Internet at http://www.celsion.com.The call will be archived for replay on Monday, November 15, 2010 at 6:00 p.m. Eastern Time and will remain available until Monday, November 22, 2010. The replay can be accessed at 1-877-870-5176 (Toll free U.S./Canada) or 1-858-384-5517 (Toll/International) using Replay Pin: 4428936. An audio replay of the call will also be available on the Company's website, http://www.celsion.com, for 30 days after 5:00 p.m. Eastern Time on November 15, 2010.

    About ThermoDox®ThermoDox® in combination with hyperthermia has the potentia
    '/>"/>

    SOURCE Celsion Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Celsion Announces Date and Time Change for Third Quarter 2010 Financial Results Conference Call to Monday, November 15, 2010
    2. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
    3. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
    4. Par Pharmaceutical Reports Second Quarter 2008 Results
    5. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
    6. Pharmos Corporation Reports 2008 Second Quarter Results
    7. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
    8. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
    9. BMP Sunstone Reports Second Quarter 2008 Financial Results
    10. ULURU Inc. Reports Second Quarter 2008 Financial Results
    11. Immtech Reports Fiscal First Quarter 2009 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/27/2014)... The Europe Thermal Protective Clothing market ... crucial revenue forecasts. It estimates the market to ... CAGR of 7.5%, from 2013 to 2018. , ... Protective Clothing market report for a glimpse of ... various tables and figures. , http://www.micromarketmonitor.com/market/europe-thermal-protective-clothing-5957050557.html ...
    (Date:11/27/2014)... -- First articles published now available ... Elsevier , a world-leading provider of scientific, technical and ... the launch of a new journal: Extreme ... launch of Extreme Mechanics Letters is driven ... applied sciences such as micro and nanotechnologies, biotechnologies, soft ...
    (Date:11/26/2014)... 2014 (PRWEB) November 26, 2014 Publicis ... network, today announced the organization has won a total ... Awards. Digitas Health LifeBrands was honored with a Silver ... PHCG agencies received eight Awards of Excellence. , ... of pharmaceutical advertising and promotion. The Awards provide a ...
    (Date:11/26/2014)... November 26, 2014 The North ... segments the market for detailed analysis of the ... market to reach $616.3 million by 2018, growing ... 2018. , Browse through the TOC of the ... get an idea of the in-depth analysis and ...
    Breaking Biology Technology:The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 2The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 3Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 2Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 3Publicis Healthcare Wins 20 Rx Club Awards 2Publicis Healthcare Wins 20 Rx Club Awards 3The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 2The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 3
    ... Loramyc(R) Completes Patient Enrollment Ahead ... Zensana(TM) Reformulation Complete, Resubmission on Target, WOODCLIFF ... (NYSE: PRX ) today provided an update ... pipeline,products: pafuramidine, Loramyc(R) (miconazole Lauriad(R)), and Zensana(TM),(ondansetron). These ...
    ... Schering-Plough,Corporation (NYSE: SGP ) will provide a ... Hassan, chairman and chief executive officer, followed,by a ... Conference on Jan. 3, 2008, at approximately 8:45 ... "unplugged" presentation., Included in Mr. Hassan,s comments ...
    ... Schering-Plough,Corporation (NYSE: SGP ) is scheduled to ... quarter and full year on Tuesday, Feb. 12,2008., ... conduct a conference,call to review results for the 2007 ... and CEO, and other members of management,will host the ...
    Cached Biology Technology:Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 2Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 3Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 4Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 5Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference 2Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result 2
    (Date:11/5/2014)... of biology in the UTSA College of Sciences, ... selected to receive a two-year $300,00 National Science ... (EAGER). The funding supports President Obama,s BRAIN Initiative, ... new technology that will demystify complex brain processes. ... neuroscience are broken into the interactions of multiple ...
    (Date:11/5/2014)... de Janeiro, Brazil -Individuals show great diversity in their ... males and females greatly differ in their perceptual evaluation ... of smell tests. , Sex differences in ... behaviors and may be connected to one,s perception of ... emotions. Thus, women,s olfactory superiority has been suggested to ...
    (Date:11/4/2014)... the right time might actually help boost a species, ... in understanding animal populations, pest control and managing fish ... journal Trends in Ecology and Evolution , a ... kind of positive population effect an overall species experiences ... the size and developmental stage of the creatures that ...
    Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3The female nose always knows: Do women have more olfactory neurons? 2When less is more: Death in moderation boosts population density in nature 2
    ... of copying the body’s own natural "waste disposal" chemistry to ... percent of patients with urea cycle disorders --- most of ... New England Journal of Medicine summarizing a quarter century of ... phenylacetate and sodium benzoate, two chemicals the body already makes ...
    ... the government of The Gambia is encouraging citizens living ... to try an unproven herbal remedy. The HIV Medicine ... his unproven claims that the treatment "cures" AIDS. ... treatment to a handful of patients who had been ...
    ... isn’t such a good thing after all. , ... say they have confirmed what other scientists have only ... can help build stronger immune systems, and may protect ... that infants who were exposed to high levels of ...
    Cached Biology News:An 'elegant' idea proves its worth 25 years later 2HIVMA opposes The Gambia's unproven AIDS remedy 2Early exposure to indoor fungus molecules may protect infants against future allergies 2